Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
Using integrative multiomics to explain myeloma progression and evolution of refractory disease
01:12
|
Download MP3
Related Videos
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
2:08
The VENICE-1 trial: venetoclax monotherapy in R/R CLL
1:31
Frontline treatment for CLL: the changing paradigm
1:26
Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions
2:01
The evolution of BCL2 inhibition in CLL
0:44
Early detection and interception across hematological cancers
3:56
Autoimmune cytopenias in CLL and the impact of targeted therapies
2:16
The unmet needs of patients who have visual impairment as a consequence of SCD
2:06
Introducing molecular diagnostics to improve leukemia care in developing countries
2:13
Personalizing the timing of SCT in patients with myelofibrosis
1:13
The main treatment goals in LR-MDS and how these differ from HR-MDS
1:44
Advances in mouse models for studying CLL and Richter's transformation
2:55
A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib
0:47
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
2:00
Areas of research currently being explored for ultra-high-risk multiple myeloma
10:42
A detailed overview of the current and emerging gene therapies for hemophilia A & B
1:17
Frailty-adapted therapy in myeloma: session takeaways
0:43
Exciting advancements in NHL from EHA 2024
1:51
BTK degraders for CLL: agents that are currently in development
3:08 5:11 2:08 1:31 1:26 2:01 0:44 3:56 2:16 2:06 2:13 1:13 1:44 2:55 0:47 2:00 10:42 1:17 0:43 1:51
